# A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

> **NCT02168530** · PHASE2 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** placebo
- **DRUG:** vismodegib

## Key facts

- **NCT ID:** NCT02168530
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02168530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02168530, "A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02168530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*